ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Ovarian Cancer

Ovarian Cancer

A large, prospective analysis showed that risk factors for ovarian cancer demonstrate substantial heterogeneity in their associations with histologic subtypes of the disease.

In this video Dr. Odunsi discusses a new study that found that higher T-cell diversity in ovarian cancer is associated with poor overall survival.

Despite hematologic toxicities and port-related adverse events, IP carboplatin plus IV dose-dense paclitaxel appears to be effective in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.

Baseline quality of life measures predict early cessation of chemotherapy and overall survival in women with platinum-resistant/refractory, recurrent ovarian cancer.

Extending platinum-free interval with pegylated liposomal doxorubicin, topotecan, or gemcitabine does not improve overall survival among patients with recurrent ovarian cancer.

Hormone maintenance therapy is associated with better survival than post-treatment surveillance for women with low-grade serous carcinoma of the ovary or peritoneum.

Among women previously treated with neoadjuvant chemotherapy followed by debulking surgery for advanced epithelial ovarian cancer, adding intraperitoneal to intravenous administration of postsurgical chemotherapy appears to be associated with a lower rate of disease progression.

Pages

Subscribe to Ovarian Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.